#Canada #Calgary #Innocan Pharma #LPT-CBD #Göttingen Minipigs

Innocan Pharma's Promising Findings on LPT-CBD in Göttingen Minipigs

Innocan Pharma Corporation has made significant strides in its pursuit of a new cannabis-based treatment, as evidenced by its latest research on LPT-CBD (Liposomal-Cannabidiol). In a recent study involving Göttingen Minipigs, which are recognized for their close physiological and metabolic similarities to humans, the company reported encouraging results that could support the ongoing development of this innovative therapeutic option.

The research was published in the reputable journal Precision Nanomedicine, showcasing the pharmacokinetics and safety characteristics of LPT-CBD following a single subcutaneous injection. Over a span of 28 days, the study demonstrated that CBD levels in the plasma of the minipigs remained elevated, suggesting prolonged therapeutic effects through this administration route.

Key Findings

The experimentation involved both Göttingen Minipigs and rabbits, where the animals received escalating doses of LPT-CBD. The outcomes highlighted several crucial points:

1. Sustained CBD Levels: The minipigs maintained significant plasma concentration of CBD for almost a month post-injection, indicating a robust and sustained release profile that can contribute to effective long-term treatment solutions.

2. Metabolic Similarity to Humans: Notably, the metabolism of CBD in the minipigs mirrored human metabolism, particularly in the breakdown of CBD into its active metabolite, 7-COOH-CBD, which is a crucial factor in understanding the drug's efficiency and safety in human applications.

3. Safety Profile: Throughout the study duration, researchers did not observe any adverse effects in the minipigs. They exhibited tolerability to the drug, and no local reactions at the injection site were detected, coupled with only minimal histopathological findings. This reassuring safety profile positions LPT-CBD favorably for potential human trials.

The Importance of Göttingen Minipigs

Göttingen Minipigs have gained recognition as a valuable animal model for drug safety evaluation, a fact that regulatory bodies often endorse. Their anatomical similarities to humans provide researchers with a valuable insight into the pharmacokinetics, toxicity, and overall drug evaluation process. This makes them a reliable model for the preclinical testing of new therapeutic agents.

Professor Chezy Barenholz, who heads the advisory board at Innocan Pharma, commented on the significance of the study, stating, “This research, alongside similar findings from various animal models, confirms the effectiveness of CBD’s sustained release from a single injection of LPT-CBD. The encouraging safety results underscore its potential applicability in human medicine.”

Dr. Eyal Kalo, Vice President of Research and Development at the company, noted, “Innocan has successfully aligned with the FDA regarding our non-clinical development strategy. This foundational study sets the stage for further exploration into the pharmacokinetics and safety of LPT-CBD in adherence to regulatory standards.”

Future Directions

Innocan Pharma's ongoing commitment to innovation highlights the significant potential of LPT-CBD in therapeutic solutions. With the foundation laid through this study, the company is well-positioned to move forward with clinical trials, aiming to revolutionize pain management without the need for opioids.

Not only does Innocan stand at the forefront of biopharmaceutical advancements, but it also promotes a holistic approach through its wellness product lines designed for self-care. Their emphasis on both pharma and consumer healthcare represents a dual commitment to improving lives through innovative solutions.

For more information on their progress and product offerings, visit Innocan Pharma's official website.

In conclusion, the promising results from this groundbreaking study mark a pivotal moment for Innocan Pharma as they take significant steps toward making LPT-CBD a viable treatment option for patients in need.